Treatment of hr+/her2- breast cancer using sacituzumab govitecan
AssigneeGilead Sciences, Inc.
InventorsSee-Chun Phan, Wendy J. Verret
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of treating a HR+/HER2- breast cancer in a human subject, wherein the subject has received previously endocrine-based therapy and at least two additional systemic therapies, comprising administering a pharmaceutical composition comprising SG.
Claims12
A method of treating HR+/HER2- breast cancer in a population of human subjects that is statistically significantly superior to a treatment of physician's choice (TPC), comprising administering to the human subjects sacituzumab govitecan (SG), wherein the human subjects previously received an endocrine-based therapy and at least two additional systemic therapies, wherein a dosage of 10 mg/kg of SG is administered as an intravenous infusion once weekly on day 1 and day 8 of one or more 21-day treatment cycles, and wherein the method achieves a statistically significantly greater overall survival (OS) compared to a control group of human subjects treated with the TPC.
Dependencies are inferred from the claim text.